

For Immediate Release
Net Profit up 144% to Rs 301 crores
Profit before Tax up 131% to Rs 368 crores

Vadodara July 22nd, 2020

Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 30th June 2020.

Financial Highlights for Q1FY21

- Net Sales up 41% to Rs 1341 crores
- Profit before tax up 131% to Rs 368 crores
- Net Profit up 144% to Rs 301 crores

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said

“It was an excellent quarter for the company backed by growth in all the international markets. Despite exceptionally challenging circumstances, the operating teams ensured profitability and growth.”

Operational Highlights

International Business

- International formulations grew 70% to Rs 771 crores in the quarter.
- US Generics grew 73% to Rs 596 crores in the quarter.
- Ex-US International Formulations grew 62% to Rs 175 crores in the quarter.
- 6 ANDA approvals received during the quarter, Cumulative ANDA approvals at 125 (including 14 tentative).
- 8 ANDA filings during the quarter; Cumulative ANDA filings at 191.

India Formulations Business

- India formulations business for the quarter de-grew by 6% to Rs 306 crores.



ALEMBIC PHARMACEUTICALS LIMITED

